Roche to Acquire 89bio in $3.5 Billion Deal Bolstering its MASH Pipeline
The definitive merger agreement, valued at up to $3.5 billion, grants Roche control of the late-stage FGF21 analog, pegozafermin, for
Read more
Inflammatory Diseases
WuXi Biologics Enters Agreement with Candid Therapeutics on Trispecific T-cell Engager
WuXi Biologics, a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), announced today, a new partnership with Candid Therapeutics,
Read more
Roche Enters $7.1 Billion Deal to Acquire Telavant
Swiss pharma giant Roche has entered an agreement to purchase Telavant Holdings, a Roivant company, owned by Roivant Sciences Ltd.
Read more
AstraZeneca’s Fasenra Achieves Primary Objective in Phase III Trial in EGPA
The MANDARA Phase III trial marks the first head-to-head comparison of biologics in treating eosinophilic granulomatosis with polyangiitis (EGPA), putting
Read more
Sandoz Strengthens Immunology Portfolio with Samsung Bioepis Deal to Commercialize Biosimilar Ustekinumab
The partnership with Samsung Bioepis Grants Novartis’ generic-drugs unit Sandoz exclusive commercialization rights for biosimilar SB17 Ustekinumab in Europe and
Read more
UK Study Finds Autoimmune Disorders Affect Around One in Ten People
According to a recent UK population-based study published in The Lancet, approximately one in ten individuals are now affected by
Read more
MyMD and Charles River Present Positive Preclinical Results for Oral TNF-α Inhibitor MYMD-1® in Rheumatoid Arthritis
MyMD Pharmaceuticals, Inc.®, a clinical stage biopharma company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and
Read more
EC Approves Sanofi and Regeneron’s Dupixent® for Eosinophilic Esophagitis
The European Commission has authorised Sanofi and Regeneron’s Dupixent® (dupilumab) as the first and only therapeutic therapy for eosinophilic esophagitis.
Read more
Tezepelumab gets ODD in the US for Eosinophilic Esophagitis
Tezepelumab, developed by AstraZeneca in collaboration with Amgen, has been granted Orphan Drug Designation (ODD) in the US FDA for
Read more
Japan’s MHLW Approves Pfizer’s CIBINQO® for Atopic Dermatitis
Pfizer has reported that the Japanese Ministry of Health, Labour and Welfare (MHLW) authorized CIBINQO® (abrocitinib), a novel therapy for
Read more